Melanotan-2: The Photoprotective & Melanogenic Peptide Research Guide

What is Melanotan-2?

Melanotan-2 (MT-2) is a cyclic heptapeptide analog of alpha-Melanocyte Stimulating Hormone (α-MSH). Originally developed at the University of Arizona, it was designed as a potential tool for preventing skin cancer by inducing a protective tan without requiring extensive UV exposure.

MT-2 is significantly more stable and potent than natural α-MSH, with a longer half-life that allows for sustained activation of the body's pigment-producing cells.

Mechanism: MC1R vs. MC4R

Melanotan-2 is a non-selective agonist, meaning it binds to multiple receptors throughout the body. Its two most researched effects stem from two distinct receptor types:

MC1R (Skin & Hair)

Binding to MC1R on melanocytes triggers the production of Eumelanin (dark pigment). This process, called melanogenesis, increases the skin's natural "sun block" capability in research models.

MC4R (Central Nervous System)

Activation of MC4R in the hypothalamus is associated with two secondary effects observed in research: increased sexual desire (libido) and decreased food intake (appetite suppression).

Photoprotection & Tanning Research

The core of MT-2 research involves its role in photoprotection. By darkening the skin through biological rather than radiation-based means, researchers observe:

• Reduced Erythema: Lower incidence of "sunburn" or skin reddening during UV exposure.
• Sustained Pigmentation: The induced tan often lasts significantly longer than a UV-based tan.
• Uniform Results: Research models often show more even pigmentation across different skin types.

Libido & Sexual Function

During early clinical trials, researchers noted unexpected increases in sexual arousal among subjects. This led to a separate branch of research into MT-2 as a potential treatment for erectile dysfunction and female sexual arousal disorder. While it proved effective, its systemic side effects (like nausea) shifted the focus toward more selective analogs like Bremelanotide (PT-141).

Research Protocols & Dosing

• Administration: Subcutaneous injection.
• Loading Phase: Often starts at 250 mcg daily to assess tolerance and build pigment.
• Maintenance Phase: 500 mcg to 1 mg, 1–2 times per week.
• Side Effects: Nausea, facial flushing, and yawning are almost universal during initial administration.
• Storage: Lyophilized powder should be stored in the freezer. Reconstituted solution must be refrigerated.

Frequently Asked Questions